Using E-Nose Technology for Non-Small Cell Lung Cancer
This study is looking at a new technology called "breathprinting" or electronic nose (E-Nose) to see if it can track how well treatment is working for people with non-small cell lung cancer (NSCLC). The E-Nose measures changes in chemicals in your breath. Researchers will collect breath samples at different times: before treatment, during treatment, and after surgery for up to two years. They will also collect blood samples at the same times. This study is for adults aged 18 and older who have untreated NSCLC that can be treated with surgery or a combination of treatments. The main goals are to see how well the E-Nose can predict how your cancer responds to treatment and if the cancer progresses. The study is currently unclear on its recruitment status and plans to enroll 60 participants.
- Study design
- This is an interventional study, meaning participants will receive specific interventions. It plans to enroll 60 participants.
- What's involved
- You would provide breath samples and blood samples at several points: before treatment, 2 weeks after neoadjuvant therapy, 2 weeks after surgery, 6 months after surgery, and then every 6 months for the first 2 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 2 years to track pathological response and progression of the cancer.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
7 sites across 2 statesStudy leadership
- Gaetano Rocco, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- pathological response (Cohort 1: stages II to IIIB)up to 2 years
obtained using E-nose technology, all patients who have pre-neoadjuvant treatment E-nose testing, pre-surgery E-nose testing, 2 week post-surgery E-nose testing, and E-nose testing every 6 months for 2 years will be considered evaluable for the primary endpoint of Major Pathologic Response (MPR). Patients with MPR confirmed on pathologic analysis will be considered to have had an MPR, whereas all other evaluable patients will be considered to have not had an MPR, in accordance with the intention-to-treat analysis.
- progression (Cohort 1: stages II to IIIB)up to 2 years
Differences in VOC expression between time-point assessments will be calculated in terms of VOC percentage change from baseline to assess the magnitude of change among patients with and without progression, particularly at earlier time points. Here, progression is considered as a binary endpoint, where progression includes recurrence, disease progression, or death within 2 years.
- progression (Cohort 2: Stage I)up to 2 years
Differences in VOC expression between time-point assessments will be calculated in terms of VOC percentage change from baseline to assess the magnitude of change among patients with and without progression, particularly at earlier time points. Here, progression is considered as a binary endpoint, where progression includes recurrence, disease progression, or death within 2 years.